Alnylam Pharmaceuticals, Inc. (ALNY) Earnings History
Annual and quarterly earnings data from 2002 to 2025
Loading earnings history...
ALNY EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ALNY Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 81.8% | 13.5% | 8.4% |
| 2024 | 85.6% | -7.9% | -12.4% |
| 2023 | 83.0% | -15.4% | -24.1% |
| 2022 | 83.7% | -75.7% | -109.0% |
| 2021 | 83.4% | -83.9% | -101.0% |
Download Data
Export ALNY earnings history in CSV or JSON format
Free sign-in required to download data
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings Overview
As of May 8, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) reported trailing twelve-month net income of $577M, reflecting +206.9% year-over-year growth. The company earned $4.18 per diluted share over the past four quarters, with a net profit margin of 8.4%.
Looking at the long-term picture, ALNY's historical earnings data spans multiple years. The company achieved its highest annual net income of $314M in fiscal 2025, representing a new all-time high.
Alnylam Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 81.8%, operating margin of 13.5%, and net margin of 8.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including IONS (-$327M net income, -40.4% margin), ARWR (-$301M net income, -0.2% margin), NTLA (-$413M net income, -609.9% margin), ALNY has outperformed on profitability metrics. Compare ALNY vs IONS →
ALNY Earnings vs Peers
Earnings metrics vs comparable public companies
ALNY Historical Earnings Data (2002–2025)
24 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $314M | +212.8% | $502M | $2.33 | 8.4% | 13.5% |
| 2024 | -$278M | +36.8% | -$177M | $-2.18 | -12.4% | -7.9% |
| 2023 | -$440M | +61.1% | -$282M | $-3.52 | -24.1% | -15.4% |
| 2022 | -$1.13B | -32.6% | -$785M | $-9.30 | -109.0% | -75.7% |
| 2021 | -$853M | +0.6% | -$709M | $-7.20 | -101.0% | -83.9% |
| 2020 | -$858M | +3.1% | -$828M | $-7.46 | -174.1% | -168.1% |
| 2019 | -$886M | -16.4% | -$939M | $-8.11 | -403.2% | -427.5% |
| 2018 | -$761M | -55.1% | -$815M | $-7.57 | -1016.6% | -1087.6% |
| 2017 | -$491M | -19.7% | -$500M | $-5.42 | -545.9% | -556.2% |
| 2016 | -$410M | -41.4% | -$425M | $-4.79 | -869.6% | -900.3% |
Full ALNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ALNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALNY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALNY — Frequently Asked Questions
Quick answers to the most common questions about buying ALNY stock.
Is ALNY growing earnings?
ALNY EPS is $4.18, with earnings growth accelerating to +206.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $577M.
What are ALNY's profit margins?
Alnylam Pharmaceuticals, Inc. net margin is +8.4%, with operating margin at +13.5%. Margins sit within typical range for the sector.
How consistent are ALNY's earnings?
ALNY earnings data spans 2002-2025. The accelerating earnings trend is +206.9% YoY. Historical data enables comparison across business cycles.